Investment case
Forte Biosciences, Inc.
FBRX · 2 developments mapped · last assessed 2026-08-27
Market Ontology has mapped 2 macro, policy, and market developments to Forte Biosciences, Inc. since 2026-08-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for FBRX yet, so no modelled value is shown. The FBRX valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run FBRX on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Forte Biosciences, Inc. Files Recommendation Statement Regarding Third-Party Tender Offer
Direct impact on share price due to tender offer premium and potential acquisition completion. Uncertainty regarding the offer's success or competing bids.
· Moves probability of acquisition completion, acquisition premium, future growth prospects if acquisition fails
What changed, by assumption
- 2026-08-19Forte Biosciences, Inc. Files Recommendation Statement Regarding Third-Party Tender Offer
- 2026-08-27Forte Biosciences, Inc. Completes Acquisition or Disposition of Assets
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-27 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-08-27 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-08-27 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
| 2026-08-24 | Terminal growth | Bearish | Guggenheim Securities used an illustrative perpetual growth rate of negative 50.0%, reflecting continued decline in revenue following assumed global loss of exclusivity for FB102 in 2043. | 1.00 |
| 2026-08-24 | Cost of capital | Bullish | Guggenheim Securities used a discount rate range of 11.75% - 14.50% based on its estimate of the Company’s weighted average cost of capital. | 1.00 |
| 2026-08-06 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-08-06 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
| 2026-07-27 | Valuation multiple | Bullish | Target re-rates to bid premium until close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-27 | Forte Biosciences, Inc. Completes Acquisition or Disposition of Assets | mixed | 1-3m | 0.70 |
| 2026-08-19 | Forte Biosciences, Inc. Files Recommendation Statement Regarding Third-Party Tender Offer | mixed | 1-3m | 0.90 |